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Abstract: In The Gambia, West Africa, the prevalence of chronic hepatitis B virus (HBV) infection in adults
exceeds eight percent and hepatocellular carcinoma (HCC) has been the most frequent type of malignancy. Two
population-based intervention studies to control HBV infection, namely, GHIS (Gambia Hepatitis Intervention
Study) and PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa), are discussed. The GHIS started in
1986 as a nation-wide trial of the HBV vaccine to evaluate the effectiveness of infant HBV vaccination in
preventing HCC in adulthood. The vaccine was progressively introduced into the Expanded Program of
Immunization (EPI) of The Gambia over four years in a phased manner, called the “stepped-wedge” design. This
was because instantaneous universal vaccination in the country was impossible for logistic and financial reasons.
However, this design also allowed the study to have an unvaccinated control group which consisted of the
newborns of the areas where HBV vaccine has not yet been incorporated in the EPI. To assess the outcome, a
national cancer registry was founded and all HCC patients in this birth cohort are linked with the vaccine trial
database. The study is still ongoing to answer whether the HBV vaccine in infancy prevent HCC in adulthood in
The Gambia.
Although the universal HBV vaccination since 1990 has been successful in reducing the prevalence of chronic
HBV infection in young Gambians, the number of HCC cases may not decline over the next decades as people
infected prior to the immunization program are likely to continue to develop the diseases. To reduce the HCC
incidence through community-based screening of HBV infection and provision of antiviral therapy, the
PROLIFICA project started in 2011. Study hypothesis and design of these two studies, GHIS and PROLIFICA,
are further discussed.
Key words: Hepatitis B, carcinoma, hepatocellular, hepatitis B vaccines, antiviral agents, public health,
epidemiology, The Gambia, Africa
INTRODUCTION
The Gambia is the smallest country in the African
continent with a population of 1.73 million people. The
UK Medical Research Council (MRC) established its
branch in The Gambia in 1947. Since that time, the MRC
Gambia has been producing numerous important studies,
which hugely influenced the global public health. My pre-
sentation will focus on study hypotheses and designs of
two population-based intervention studies to control hepa-
titis B virus (HBV) infection in The Gambia, namely
GHIS and PROLIFICA. The GHIS stands for the Gambia
Hepatitis Intervention Study, which is a hepatitis B vaccine
field trial started in 1986. The project was originally fun-
ded by the Gambian government, WHO-IARC (Interna-
tional Agency for Research on Cancer), Italian
Government and MRC. The second study, PROLIFICA
stands for Prevention of Liver Fibrosis and Cancer in
Africa. This is to treat chronic hepatitis B carriers with
antiviral treatment and started in 2011. The study is funded
by the European Union, MRC and Imperial College
London. As I am working within PROLIFICA but not in
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the GHIS, my talk on GHIS is based on the historical liter-
atures that I read.
GHIS (GAMBIA HEPATITIS INTERVENTION STUDY)
Background
When the GHIS was prepared in the early 1980’s,
there had been accumulating evidence that there is etiolog-
ical association between HBV infection and hepatocellular
carcinoma (HCC) [1]. It was also well known that sub-
Saharan Africa (SSA) is highly endemic for HBV infection
and most of transmission occurs during childhood rather
than perinatal mother-to-infant transmission [2]. As a pre-
vention, plasma-derived hepatitis B vaccine was already
shown to be effective against acute and chronic HBV
infection [3]. However, there were two important ques-
tions: how long the immunity lasts after the vaccine and
whether the vaccine can prevent HCC, which is the most
important complication of chronic HBV infection [4].
There was a dilemma among public health experts
about the use of hepatitis B vaccine in SSA: whether to
immediately start mass vaccination campaigns in SSA or
to conduct randomized controlled trials before such pro-
grams to have direct evidence that the vaccine prevents
HCC [4]. Both strategies have pros and cons. Mass vacci-
nation would be challenging because the cost of the vac-
cine was still high and the availability of vaccine was
limited at that time. In contrast, randomized controlled trial
would present ethical problems because this study design
creates a group of people who do not receive the vaccine,
which was already proven to be at least effective against
chronic carriage of infection. Moreover, randomizing chil-
dren at an individual level would pose logistic challenges
given the planned size of the study.
After considering these, the GHIS finally started in an
attempt to evaluate the protective effectiveness of infant
hepatitis B vaccination on the incidence of HCC in adult-
hood. The vaccine was incorporated into the existing EPI
(Expanded Program of Immunization) program in The
Gambia without adding any new additional schedule, at
birth and month 2, 4, and 9 (Fig. 1).
Hepatitis B vaccine trial
The design of this study was called “stepped wedge
design” (Fig. 2) [4]. As instantaneous introduction of
nation-wide hepatitis B vaccine was impossible at that
time due to financial and logistic constraint, it was decided
to introduce the vaccine in a phased manner on a group by
group basis until the entire population is covered. The
Gambia was covered by 17 EPI teams, and one of the 17
teams was randomly selected as the first team to start inte-
grating the hepatitis B vaccine in the program. Since July
1986, all children born in the area covered by the first EPI
team were given hepatitis B vaccine, while other children
who were born in other areas became the unvaccinated
controls. Three months later, the second area that had been
randomly selected started providing hepatitis B vaccine.
Then, all newborns in the first and second areas received
the vaccine, whereas those born in other areas did not. It
was four years after the first team had started that the
whole country was covered with hepatitis B vaccine. This
progressive introduction of vaccine between 1986 and
1990 resulted in 61,000 vaccinated and 63,000 unvaccina-
ted newborns [5]. Without compromising the ethical issue,
the GHIS could have an unvaccinated control group. Of
note, the statistical power of this approach is > 70% of that
of a simple randomization in which one-half of the EPI
teams are allocated to give hepatitis B vaccine.
Fig. 1. The objective and immunization schedules of the
GHIS.
Fig. 2. Study design of the GHIS.
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Measuring the outcome
Next was to measure the outcome, which is HCC.
HCC does not occur 1 or 2 years after the infection; it usu-
ally takes decades to develop. In 1986, GHIS established
The Gambia National Cancer Registry in order to capture
all the incident cases of cancer within the country [6].
Whenever a staff in the Registry is notified of a new can-
cer case, both the clinical and demographic information
such as name, sex, year of birth, birthplace and name of
parents were collected. The demographic information of
the HCC patients who were born in The Gambia between
1986 and 1990 will be linked with information kept in the
vaccination database, allowing identification of the vacci-
nation status of the individual (Fig. 3). The site of BCG
scar would also help to distinguish whether or not the per-
son received the hepatitis B vaccine. BCG had been given
on the left forearm in the hepatitis B vaccination group and
on the right in the control group. In addition, foot and palm
prints that were taken when the child entered the study will
be compared with foot and palm prints of the HCC patients
for linkage [4].
How long will it take to have final results? In order to
calculate this, several assumptions were required (Fig. 4).
These include vaccine coverage, hepatitis B vaccine effi-
cacy against chronic infection, impact of perinatal infec-
tion, which is a major cause of vaccine failure, and
proportion of HCC attributable to HBV infection [5]. It
was estimated that this would take 30 to 35 years, so
within a few years this public health question may be
answered. However, the study naturally produced many
intermediate endpoints before reaching this final result.
One of them is, for example, vaccine efficacy against
chronic carriage after 20 years was 94% [7]. This suggest-
ed that booster vaccines may not be necessary at least until
that age. And more importantly, the study could show that
Fig. 3. Outcome measurement in the GHIS.
the introduction of hepatitis B vaccination into the EPI was
feasible in an African country [8].
PROLIFICA (PREVENTION OF LIVER FIBROSIS AND
CANCER IN AFRICA)
Background
Thanks to GHIS and other vaccine trials in 1980’s,
feasibility of the HBV vaccination program and its effec-
tiveness against chronic infection was well established. In
The Gambia, national infant hepatitis B vaccination pro-
gram replaced the GHIS when the vaccine trial finished in
1990. Meanwhile, the price of hepatitis B vaccine dramati-
cally reduced. Based on these, in 1992, WHO recommen-
ded all member states to include hepatitis B vaccine as a
universal vaccination by 1997. By the end of 2012, 181
countries adopted this [9]. However, widespread use of
this effective vaccine gave a false impression that HBV
infection is no longer an important public health problem.
Indeed, one of the Millennium Development Goals is spe-
cific for infectious diseases and this only includes HIV,
malaria, and tuberculosis. Other tropical infectious disea-
ses formed the group called tropical neglected disease, but
viral hepatitis is not included. There seems to be no place
for viral hepatitis in the global health agenda [10].
However, the health burden associated with HBV
infection is still substantial. In 2005, prevalence of HBV
infection in adults still remains high in SSA exceeding 8%
in some countries [11]. Global burden of disease and injury
study [12] estimated that out of 235 causes of deaths, liver
cirrhosis ranked at 12th and liver cancer ranked at 16th in
2010. HBV infection ranked at 15th. These figures reflect
that even though hepatitis B vaccination programs were
Fig. 4. Assumptions needed for the sample size calculation in
the GHIS.
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included in many countries, the people who had been
infected before the introduction of the vaccination pro-
grams continue to suffer from carriage of HBV infection
and also HCC [13]. We will probably see an increasing
number of HCC patients over the next five to six decades
in countries where HBV is endemic [14]. Then, do we just
wait until they die without taking any action? Of course,
not. We must consider treating chronic HBV carriers to
prevent premature deaths from HCC. However, the access
to HBV treatment is still largely limited in high endemic
countries which are often resource-limited.
Before starting treatment for chronic HBV carriers in
SSA, there are several questions to answer. Is there any
effective treatment? Yes, there are good medicines called
nucleos(t)ide analogues, which can be taken orally and are
very effective in reducing the amount of virus [13]. It is
different from 15 years ago when only interferon was
available, which caused many side effects and was not
effective in all patients. Are nucleos(t)ide analogues
expensive? No; the Global Fund generic price of tenofovir,
a nucleos(t)ide analogue, is less than ¥10,000 (100 USD)
per year. Don’t you need a liver biopsy and histopatholo-
gist to select a patient who needs treatment? Yes, assessing
the degree of liver fibrosis is important for the treatment
initiation, however, now there are alternative noninvasive
methods to measure liver fibrosis [15]. Then, the last ques-
tion is: how can you deliver the care and treatment? We
can just learn from the HIV program. However, unfortu-
nately, there is still ongoing discrimination regarding
access to antiviral therapy. For example tenofovir, which is
effective for both HIV and HBV, has been freely available
in some African countries. However, some donors still
refuse to use this drug for HBV mono-infected patients
[16].
Study design
It was in such a context that PROLIFICA started in
2011 in The Gambia and Senegal. The primary objective is
to assess whether antiviral therapy using tenofovir reduces
the incidence of HCC in West Africa. Another objective is
to determine applicability and effectiveness of population-
based screening, clinical assessment and treatment in West
Africa.
Before treating someone, we have to identify chronic
carriers of HBV. For example, antenatal care or blood
banks would be easy places to find chronic carriers.
However, we have been conducting a community-based
screening, because our target is the general population in
The Gambia. This is the original plan (Fig. 5). Our aim is
to have 5,500 people for the screening. Assuming the prev-
alence of HBV infection is 15%, we will have 825 people
who carry the virus. They are all invited to the liver clinic
for further investigation. Chronic HBV carriers who meet
the treatment criteria of international guidelines (EASL
(European Association for the Study of the Liver) guide-
lines) are treated with tenofovir, while those who do not
meet treatment criteria are followed without antiviral ther-
apy for 5 years. Because tenofovir was already proven to
be effective for chronic HBV infection, a clinical trial hav-
ing a control group was considered unethical. The inci-
dence rates of HCC in the treatment and observation
groups will be compared with historical data from the
Gambia National Cancer Registry. Together with Senegal,
we estimated to have 300 carriers eligible for tenofovir. At
this sample size, the study will have 71% power to detect a
treatment efficacy of 60% at the 5% level of statistical sig-
nificance over three years.
Community-based screening
We targeted the Western region of the country
(Fig. 6) and because the distribution of other risk factors
for HCC, such as consumption of crops contaminated by
aflatoxin, was thought to differ between urban and rural
areas [17], we stratified the area. Out of 1,450 enumeration
areas defined by the Gambia Government for census pur-
pose, we randomly selected 40 urban and 40 rural areas.
Fig. 5. Recruitment plan of the PROLIFICA.
Fig. 6. Map of The Gambia showing the Western Region.
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All people over 30 years old who live in those selected
areas are eligible. We set 30 years old as a cutoff because
those less than 30 years are likely to have been vaccinated
with hepatitis B vaccine.
In each area, we start by visiting the head of village to
explain the purpose of the screening (Fig. 7). Then, once
the approval from the head of village is obtained, we
organize the community meeting. We bring the poster and
leaflets and explain about our project to the villagers. After
the meeting, we register all eligible persons who are living
in the area. Then, we set up a screening point at the center
of the village such as mosque or health center. After
informed consent, screening for HBV infection is per-
formed using point-of-care test, which gives us a result
within 15 minutes. We do post-test counseling on site and
those who tested positive are invited to the liver clinic usu-
ally one week later. At the liver clinic at the MRC Gambia
we perform clinical examinations including abdominal
ultrasound and Fibroscan, which is a noninvasive method
to measure the liver fibrosis. Blood is collected and tested
for hematology, biochemistry, HBV markers, HBV DNA
and other viral co-infections. All the information necessary
to assess patients’ eligibility for the antiviral treatment are
collected.
Future of the study
Some patients under the treatment may clear the
infection before the study ends, and we may able to stop
the treatment. However, substantial number of patients
may require life-long treatment. At the end of the study,
we expect that the treatment program continues for the
study participants either through raising new funds for fur-
ther study or through integrating the program into the
national healthcare system.
Fig. 7. Flow of procedures in the community-based screening.
CONCLUSIONS
The GHIS and PROLIFICA are good examples of
population-based field intervention studies in resource-
poor settings. These pragmatic studies are set to determine
how best interventions can be applied in populations and
what impact they have in improving the people’s health
under the circumstances of general use. To conduct such a
study, there are several requirements. First, a detailed
study planning is imperative. This includes all aspects of
an investigation, from formulation of specific study ques-
tions which determine the study objectives, through prepa-
ration for logistics, collection of data and its analysis, to
dissemination of results [18]. Evidence derived from well
planned field trials can guide public health policy, as dem-
onstrated by GHIS. Second, the study design needs to be
locally adapted, and consider fully the ethical implications.
Third, it is important to involve researchers from a wide
range of disciplines in designing and conduct of the study:
from molecular biologists to medical anthropologists.
Finally, the study needs to be “population-based” and
study participants must be representative of the population.
At the end of the study, the investigators expect the project
to be integrated into the national public health system as
mass vaccination or mass screening programs, and these
will be for the entire population. We are not interested in
subsets of people who can afford to come to medical facili-
ties.
QUESTIONS AND DISCUSSION
Tetsu Yamashiro Thank you Dr. Shimakawa. You pre-
sented very interesting projects to us. The first one,
over 30 years of cohort study, I really appreciate the
investigators who started this project, foreseeing what
would happen in the next 30 years. In the second one,
PROLIFICA, how long the cohort will be followed?
Yusuke Shimakawa Five years.
Tetsu Yamashiro Endpoints seem to be more or less
similar between GHIS and PROLIFICA.
Yusuke Shimakawa Yes, exactly. PROLIFICA is work-
ing together with the Gambia National Cancer Regis-
try to strengthen the diagnostic capacity for liver
cancer cases.
Tetsu Yamashiro Right, the other question I would like
to address is that approaching the community in
Africa is quite different from the way you approach
the community in Vietnam or in the Philippines. To
invite the people in the community to the screening, I
guess you have got an approval from the government
health committee, but was that enough?
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Yusuke Shimakawa First, PROLIFICA is jointly organ-
ized with the Gambia Government and the ethics
committee also includes the officials from the
Government. But as you indicated, this is not enough
in The Gambia. I imagine that in Vietnam the way to
approach the community may be straightforward
within the Socialist system, once the approval from
the Government is obtained. In The Gambia, there are
several key persons in a village and it is difficult to
know who we should contact first to obtain a com-
munity approval. For example, in some villages we
had successful screenings by contacting the head of
village who was well respected by all the villagers.
But in some villages where the head of village was
absent or not functioning well, we had to contact a
councilor who lives in the areas. Consequently, vil-
lagers who do not support the councilor for political
reason did not attend the screening. Achieving high
attendance to screenings is not always easy.
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